Stockscreener 앱 받기
9.00
4.58%
-0.39
전일 마감가:
$9.39
열려 있는:
$9.23
하루 거래량:
1,302
Relative Volume:
0.24
시가총액:
$43.42M
수익:
$2.61M
순이익/손실:
$1.69M
주가수익비율:
29.97
EPS:
0.3003
순현금흐름:
-
1주 성능:
-0.44%
1개월 성능:
+15.76%
6개월 성능:
+12.70%
1년 성능:
-6.57%
1일 변동 폭
$8.76
$9.345
1주일 범위
$8.68
$9.75
52주 변동 폭
$6.55
$10.00
Daxor Corporation Stock (DXR) Company Profile
명칭
Daxor Corporation
전화
212-330-8500
주소
Empire State Building, Suite 7120 350 Fifth Avenue, New York, NY
DXR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXR
Daxor Corporation
|
9.345 | 43.42M | 2.61M | 1.69M | 0 | 0.3003 |
|
ISRG
Intuitive Surgical Inc
|
537.60 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
170.25 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.60 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
258.32 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
222.28 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Daxor Corporation Stock (DXR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-05-16 | 개시 | Ascendiant Capital Markets | Buy |
Daxor Corporation 주식(DXR)의 최신 뉴스
Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals - The Globe and Mail
(DXR) Technical Pivots with Risk Controls - news.stocktradersdaily.com
(DXR) Proactive Strategies - news.stocktradersdaily.com
(DXR) Investment Analysis - news.stocktradersdaily.com
Daxor announces new findings from Duke University on BVA - TipRanks
Daxor (DXR) Highlights Key Heart Failure Study Results | DXR Sto - GuruFocus
Daxor Announces Duke University Study on Blood Volume - GlobeNewswire
Duke Research Reveals 40% of Heart Failure Patients Misdiagnosed with Anemia, Study Shows - Stock Titan
Daxor (DXR) Expands Diagnostic Solutions Across U.S. Healthcare Systems | DXR Stock News - GuruFocus
Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems - GlobeNewswire
Daxor announces opening of new BVA program at Florida center - TipRanks
Daxor (DXR) Launches Advanced BVA Program in Tampa Bay Healthcare Center | DXR Stock News - GuruFocus
Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology - GlobeNewswire
Renaissance Technologies LLC Has $214,000 Stock Holdings in Daxor Co. (NASDAQ:DXR) - Defense World
Daxor announces expansion of BVA capabilities in three new hospitals - TipRanks
Daxor (DXR) Expands Blood Volume Analysis with New Hospital Part - GuruFocus
Daxor (DXR) Expands Blood Volume Analysis with New Hospital Partnerships | DXR Stock News - GuruFocus
Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance - GlobeNewswire
NeuroMetrix (NASDAQ:NURO) and Daxor (NASDAQ:DXR) Head-To-Head Comparison - Defense World
Daxor Corporation Secures Funding for Blood Volume Analyzer Study - Medical Product Outsourcing
Daxor stock hits 52-week low at $6.83 amid market challenges - MSN
Critical Analysis: Daxor (NASDAQ:DXR) versus Integra LifeSciences (NASDAQ:IART) - The AM Reporter
Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions - The Manila Times
Daxor Corporation to Exhibit at the 45th International - GlobeNewswire
Revolutionary Blood Volume Analysis: How Daxor's 98% Accurate Tech is Transforming Heart and Lung Care - Stock Titan
Daxor (NASDAQ:DXR) versus Integra LifeSciences (NASDAQ:IART) Head to Head Review - Defense World
(DXR) Trading Report - news.stocktradersdaily.com
Daxor Corporation to Showcase Innovative Blood Volume - GlobeNewswire
Daxor (DXR) to Exhibit at MedAxiom CV Transforum Spring'25 Conference | DXR Stock News - GuruFocus
Daxor to showcase blood volume analysis at Cardiovascular Transforum conference - TipRanks
Revolutionary Blood Volume Technology Slashes Mortality Rates by 82%Groundbreaking Clinical Results Unveiled - Stock Titan
Daxor announces new data at ACC on blood volume analysis - TipRanks
Daxor (DXR) Unveils Promising Heart Failure Study Results at ACC Conference | DXR Stock News - GuruFocus
New Research at ACC25 Shows Daxor BVA-Identified Euvolemic - GlobeNewswire
Breakthrough Heart Failure Study: Daxor BVA Test Doubles Patient Survival Rates - Stock Titan
Daxor (DXR) Submits Next-Gen Blood Analyzer to FDA for Approval - GuruFocus
Daxor submits new blood volume analyzer to FDA By Investing.com - Investing.com South Africa
Daxor Corporation Submits 510(K) To FDA For Next-Generation Blood Volume Analyzer - marketscreener.com
Daxor submits new blood volume analyzer to FDA - Investing.com
Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer - GlobeNewswire
Revolutionary Blood Volume Analyzer With Military Backing Advances Toward FDA Green Light - Stock Titan
CEO’s Bold Move: Major Investment in Daxor Stock - TipRanks
Daxor CEO Michael Feldschuh purchases over $16,000 in stock By Investing.com - Investing.com South Africa
Daxor CEO Michael Feldschuh purchases over $16,000 in stock - Investing.com Australia
DAXOR CEO Michael Richard Feldschuh Buys 2,063 Shares - TradingView
Where are the Opportunities in (DXR) - news.stocktradersdaily.com
Daxor Corporation (NASDAQ:DXR) Q4 2024 Earnings Call Transcript - MSN
Daxor (NYSEAMERICAN:DXR) Stock Passes Above 200-Day Moving Average – Here’s Why - Defense World
Daxor announces new data from Duke University on BVA at ACC - TipRanks
Daxor’s BVA technology gains traction at cardiology event - Investing.com
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo - GlobeNewswire
Daxor Corporation (DXR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Daxor Corporation 주식 (DXR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Michel Robert J | Chief Financial Officer |
Mar 10 '25 |
Buy |
8.00 |
1,000 |
8,000 |
17,050 |
| Feldschuh Michael Richard | Chief Executive Officer |
Mar 10 '25 |
Buy |
7.68 |
3,360 |
25,805 |
210,852 |
0.12%
0.02%
자본화:
|
볼륨(24시간):